Detalhe da pesquisa
1.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923550
2.
Clinical Applications of Next-Generation Sequencing in Precision Oncology.
Cancer J
; 25(4): 264-271, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31335390
3.
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Clin Lung Cancer
; 19(6): 518-530.e7, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30279111
4.
Genotype to phenotype: associations, errors and complexity.
Trends Genet
; 18(6): 283-4, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12044349
5.
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Nat Commun
; 7: 11815, 2016 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27283993
6.
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Cancer Discov
; 5(7): 713-22, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25934077
7.
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Nat Commun
; 7: 13513, 2016 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27841271